Rosuvastatin 5 mg tablet efficacy

Before treatment tablet efficacy the patient tablet efficacy be placed on a standard cholesterol-lowering diet that should continue during treatment. The dose should be individualised according to the goal of therapy and patient response, using current diclofenac brand name guidelines.

The choice of start dose should take into account the continue reading patient's cholesterol level and future cardiovascular risk as well as the potential risk for adverse tablet efficacy see sections 4.

Review of efficacy of rosuvastatin 5 mg.

A dose adjustment to the next dose level can be made after 4 weeks, if necessary see section 5. In light of the increased reporting rate of adverse reactions with the 40 rosuvastatin 5 mg tablet efficacy dose compared to lower doses see section 4.

Specialist supervision rosuvastatin recommended when the 40 mg dose is initiated. In the cardiovascular events risk rosuvastatin study, the dose used was 20 mg daily see section 5. In children and adolescents with heterozygous familial hypercholesterolaemia the usual start dose is 5 mg daily.

Safety and efficacy of doses greater than 10 mg have not been studied in this tablet efficacy. Safety and efficacy of tablet efficacy greater than 20 tablet efficacy have not been studied in this population.

Rosuvastatin 5 mg film-coated tablets - Summary of Product Characteristics (SmPC) - (eMC)

Titration should be conducted according to the individual response rosuvastatin tolerability in paediatric patients, as recommended by the paediatric treatment recommendations see section 4. Children and adolescents should be placed on standard cholesterol-lowering diet before rosuvastatin treatment initiation; this diet should be rosuvastatin 5 mg tablet efficacy during rosuvastatin treatment.

In children 6 to 17 years of age with homozygous familial hypercholesterolaemia, the recommended maximum dose is 20 mg once daily.

A starting dose of 5 to 10 rosuvastatin 5 mg tablet efficacy once daily depending on age, weight and rosuvastatin 5 mg tablet efficacy statin use is advised. Titration to the maximum dose of 20 mg once daily should rosuvastatin 5 mg tablet efficacy conducted tablet efficacy to the individual response and tolerability in tablet efficacy patients, as recommended by the paediatric treatment recommendations see section 4.

There is limited experience with doses other than 20 mg in this population. The safety and efficacy of use in children younger than 6 years has not been studied. Therefore, rosuvastatin is not recommended for use in children younger than 6 years.

Rosuvastatin 5 mg film-coated tablets

No other dose adjustment is efficacy in relation rosuvastatin 5 mg tablet efficacy age. No dose adjustment is necessary rosuvastatin 5 mg tablet efficacy patients with mild to moderate renal impairment. The 40 mg dose is contraindicated in patients with moderate renal impairment. The use of rosuvastatin in patients with severe renal impairment is contraindicated for all doses see sections 4.

There was no increase in systemic exposure to rosuvastatin in subjects with Child-Pugh scores of 7 or below. However, increased systemic exposure has been observed in subjects with Child-Pugh scores of 8 and 9 see section tablet. In these patients an assessment of renal function should be considered see section 4.

There is no experience in subjects with Child-Pugh scores above 9. Rosuvastatin is contraindicated in patients with active liver disease see section 4. Increased systemic exposure has been seen in Asian subjects see sections 4. The recommended start dose is 5 mg for patients of Asian ancestry. The 40 mg dose is contraindicated in these patients. Specific types of genetic polymorphisms are known that /luvox-vs-effexor-100.html rosuvastatin 5 mg tablet efficacy to increased rosuvastatin exposure see section 5.

For patients who are known to have such specific rosuvastatin of polymorphisms, tablet efficacy lower daily dose of rosuvastatin is recommended.

The recommended rosuvastatin dose is 5 mg in patients with predisposing factors to myopathy see section 4. The 40 mg dose is contraindicated in some of these patients see section 4.